Genetronics' EPT (electroporation therapy) targets head & neck cancer:
This article was originally published in Clinica
Executive Summary
Positive trial results supporting Genetronics Biomedical's electroporation therapy have shown that the system successfully treated 83% of patients who were diagnosed primary head and neck cancer. A four-week follow-up of the 12-patient trial revealed that, following treatment with San Diego, California-based Genetronics' proprietary electroporation system, tissue excisions from ten of the patients showed no evidence of disease, reports study leader Martin Burian, of the University of Vienna.